Ray Dalio's NTLA Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 223,166 shares of Intellia Therapeutics, Inc. (NTLA) worth $2.01 M, representing 0.01% of the portfolio. First purchased in 2022-Q1, this short-term holding has been held for 5 quarters.
Based on 13F filings, Ray Dalio has maintained this position in NTLA for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 223,166 shares. Largest reduction occurred in Q1 2023, reducing 9,387 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Intellia Therapeutics (NTLA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Intellia Therapeutics (NTLA) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +223,166 | New Buy | 223,166 | $8.99 |
| Q1 2023 | -9,387 | Sold Out | 0 | $0.00 |
| Q4 2022 | +9,387 | New Buy | 9,387 | $34.89 |
| Q2 2022 | -4,907 | Sold Out | 0 | $0.00 |
| Q1 2022 | +4,907 | New Buy | 4,907 | $72.75 |
Ray Dalio's Intellia Therapeutics Investment FAQs
Ray Dalio first purchased Intellia Therapeutics, Inc. (NTLA) in Q1 2022, acquiring 4,907 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Intellia Therapeutics, Inc. (NTLA) for 5 quarters since Q1 2022.
Ray Dalio's largest addition to Intellia Therapeutics, Inc. (NTLA) was in Q4 2025, adding 223,166 shares worth $2.01 M.
According to the latest 13F filing for Q4 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 223,166 shares of Intellia Therapeutics, Inc. (NTLA), valued at approximately $2.01 M.
As of the Q4 2025 filing, Intellia Therapeutics, Inc. (NTLA) represents approximately 0.01% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Intellia Therapeutics, Inc. (NTLA) was 223,166 shares, as reported at the end of Q4 2025.